Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

yunbai (beijing) technology co.ltd - .beta.-pinene (unii: 4ms8vhz1hj) (.beta.-pinene - unii:4ms8vhz1hj), eucalyptol (unii: rv6j6604tk) (eucalyptol - unii:rv6j6604tk), limonene, (+)- (unii: gfd7c86q1w) (limonene, (+)- - unii:gfd7c86q1w), sabinene (unii: 7d1tl44gpc) (sabinene - unii:7d1tl44gpc), .alpha.-pinene (unii: jpf3yi7o34) (.alpha.-pinene - unii:jpf3yi7o34) - deodorizing, disinfection,sterilization and mites removal pour 300 ml concentrate into the ybs deodorizing and disinfection humidifier, add pure water to the max. water level (max), or dilute the concentrate according to the concentrate-water proportion of 1: 9; finally, add it into other humidfiers for use. unscrew the cover and replace it with a spray head, adjust the buckleand spray directly for use. strong removal of odor in room and vehiclebacterial eliminating rate: 99.97% kill rate of influenza a virus: above 90% strong mites removal, with mites removal rate: above 81%nontoxic according to oral test, no skin irritation

Irland - Englisch - HPRA (Health Products Regulatory Authority)

rowex ltd - drospirenone, ethinylestradiol - film coated tablet - 0.03 / 3 milligram - progestogens and estrogens, fixed combinations

Kanada - Englisch - Health Canada

merlion pharmaceuticals gmbh - finafloxacin - suspension - 0.3% - finafloxacin 0.3% - antibacterials

Armenien - Englisch - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

csl behring gmbh - human blood coagulation factor viii - powder and solvent for solution for injection/ infusion - 500iu

Armenien - Englisch - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

csl behring gmbh - human blood coagulation factor viii - powder and solvent for solution for injection/ infusion - 1000iu

Europäische Union - Englisch - EMA (European Medicines Agency)

krka, d.d., novo mesto - efavirenz, emtricitabine, tenofovir disoproxil succinate - hiv infections - antivirals for systemic use - efavirenz/emtricitabine/tenofovir disoproxil krka is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil. it is indicated for the treatment of human immunodeficiency virus-1 (hiv-1) infection in adults aged 18 years and over with virologic suppression to hiv-1 rna levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months. patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in efavirenz/emtricitabine/tenofovir disoproxil krka prior to initiation of their first antiretroviral treatment regimen.the demonstration of the benefit of efavirenz/emtricitabine/tenofovir disoproxil is primarily based on 48-week data from a clinical study in which patients with stable virologic suppression on a combination antiretroviral therapy changed to efavirenz/emtricitabine/tenofovir disoproxil.no data are currently available from clinical studies with efavirenz/emtricitabine/tenofovir disoproxil in treatment-naïve or in heavily pretreated patients.no data are available to support the combination of efavirenz/emtricitabine/tenofovir disoproxil and other antiretroviral agents.

Europäische Union - Englisch - EMA (European Medicines Agency)

mylan pharmaceuticals limited - efavirenz, emtricitabine, tenofovir disoproxil maleate - hiv infections - antivirals for systemic use - efavirenz/emtricitabine/tenofovir disoproxil mylan is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil. it is indicated for the treatment of human immunodeficiency virus-1 (hiv-1) infection in adults aged 18 years and over with virologic suppression to hiv-1 rna levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months. patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in efavirenz/emtricitabine/tenofovir disoproxil mylan prior to initiation of their first antiretroviral treatment regimen.the demonstration of the benefit of efavirenz/emtricitabine/tenofovir disoproxil is primarily based on 48-week data from a clinical study in which patients with stable virologic suppression on a combination antiretroviral therapy changed to efavirenz/emtricitabine/tenofovir disoproxil (see section 5.1). no data are currently available from clinical studies with efavirenz/emtricitabine/tenofovir disoproxil in treatment-naïve or in heavily pretreated patients.no data are available to support the combination of efavirenz/emtricitabine/tenofovir disoproxil and other antiretroviral agents.

Europäische Union - Englisch - EMA (European Medicines Agency)

zentiva k.s. - efavirenz, emtricitabine, tenofovir disoproxil, phosphate - hiv infections - antivirals for systemic use, - efavirenz/emtricitabine/tenofovir disoproxil zentiva is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil. it is indicated for the treatment of human immunodeficiency virus-1 (hiv-1) infection in adults aged 18 years and over with virologic suppression to hiv-1 rna levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months. patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in efavirenz/emtricitabine/tenofovir disoproxil zentiva prior to initiation of their first antiretroviral treatment regimen., the demonstration of the benefit of the combination efavirenz/emtricitabine/tenofovir disoproxil is primarily based on 48-week data from a clinical study in which patients with stable virologic suppression on a combination antiretroviral therapy changed to efavir

Kanada - Englisch - Health Canada

agila jamp canada inc - gemcitabine (gemcitabine hydrochloride) - powder for solution - 200mg - gemcitabine (gemcitabine hydrochloride) 200mg - antineoplastic agents

Kanada - Englisch - Health Canada

agila jamp canada inc - gemcitabine (gemcitabine hydrochloride) - powder for solution - 1g - gemcitabine (gemcitabine hydrochloride) 1g - antineoplastic agents